4.7 Article

Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli ex vivo

Journal

DIABETOLOGIA
Volume 64, Issue 8, Pages 1866-1879

Publisher

SPRINGER
DOI: 10.1007/s00125-021-05473-9

Keywords

Adiponectin; AdipoRon; Diabetes; Diabetic kidney disease; Inflammation; Inflammatory cytokines; LPS; Obesity; Obesity-related kidney disease; Podocyte

Funding

  1. Helsinki University Central Hospital
  2. Paivikki and Sakari Sohlberg Foundation
  3. Finnish Cultural Foundation
  4. Finnish Kidney Foundation
  5. Finnish Norwegian Medical Research Foundation
  6. Sigrid Juselius Foundation
  7. Finnish Diabetes Research Foundation
  8. Jane and Aatos Erkko Foundation
  9. Doctoral Programme in Biomedicine of University of Helsinki
  10. Juhani Aho Medical Research Foundation
  11. Finska Lakaresallskapet
  12. Folkhalsan Research Foundation
  13. Helsinki University Central Hospital Research Funds
  14. Novo Nordisk Foundation [NNF OC0013659]
  15. HiLife and Faculty of Medicine, University of Helsinki
  16. University of Helsinki

Ask authors/readers for more resources

AdipoRon can alleviate renal inflammation in HFD-fed mice and improve glomerular inflammation and injury by reducing the expression of proinflammatory cytokines and inhibiting inflammatory signaling pathways, thereby decreasing apoptosis, migration, and inflammatory response.
Aims/hypothesis Chronic low-grade inflammation with local upregulation of proinflammatory molecules plays a role in the progression of obesity-related renal injury. Reduced serum concentration of anti-inflammatory adiponectin may promote chronic inflammation. Here, we investigated the potential anti-inflammatory and renoprotective effects and mechanisms of action of AdipoRon, an adiponectin receptor agonist. Methods Wild-type DBA/2J mice were fed with high-fat diet (HFD) supplemented or not with AdipoRon to model obesity-induced metabolic endotoxaemia and chronic low-grade inflammation and we assessed changes in the glomerular morphology and expression of proinflammatory markers. We also treated human glomeruli ex vivo and human podocytes in vitro with AdipoRon and bacterial lipopolysaccharide (LPS), an endotoxin upregulated in obesity and diabetes, and analysed the secretion of inflammatory cytokines, activation of inflammatory signal transduction pathways, apoptosis and migration. Results In HFD-fed mice, AdipoRon attenuated renal inflammation, as demonstrated by reduced expression of glomerular activated NF-kappa B p65 subunit (NF-kappa B-p65) (70%, p < 0.001), TNF alpha (48%, p < 0.01), IL-1 beta (51%, p < 0.001) and TGF beta (46%, p < 0.001), renal IL-6 and IL-4 (21% and 20%, p < 0.05), and lowered glomerular F4/80-positive macrophage infiltration (31%, p < 0.001). In addition, AdipoRon ameliorated HFD-induced glomerular hypertrophy (12%, p < 0.001), fibronectin accumulation (50%, p < 0.01) and podocyte loss (12%, p < 0.001), and reduced podocyte foot process effacement (15%, p < 0.001) and thickening of the glomerular basement membrane (18%, p < 0.001). In cultured podocytes, AdipoRon attenuated the LPS-induced activation of the central inflammatory signalling pathways NF-kappa B-p65, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38-MAPK) (30%, 36% and 22%, respectively, p < 0.001), reduced the secretion of TNF alpha (32%, p < 0.01), and protected against podocyte apoptosis and migration. In human glomeruli ex vivo, AdipoRon reduced the LPS-induced secretion of inflammatory cytokines IL-1 beta, IL-18, IL-6 and IL-10. Conclusions/interpretation AdipoRon attenuated the renal expression of proinflammatory cytokines in HFD-fed mice and LPS-stimulated human glomeruli, which apparently contributed to the amelioration of glomerular inflammation and injury. Mechanistically, based on assays on cultured podocytes, AdipoRon reduced LPS-induced activation of the NF-kappa B-p65, JNK and p38-MAPK pathways, thereby impelling the decrease in apoptosis, migration and secretion of TNF alpha. We conclude that the activation of the adiponectin receptor by AdipoRon is a potent strategy to attenuate endotoxaemia-associated renal inflammation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available